Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

CSPC Pharmaceutical Group (1093.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (HK$) Price Target (HK$) Rating
2022-02-289.2514.00Buy
2022-03-249.3513.00Buy
2022-08-257.9111.80Buy
2022-11-249.7912.00Buy
2023-03-237.7411.80Buy
2023-05-257.2311.60Buy
2023-07-216.3311.10Buy
2023-11-307.0510.60Buy
2024-03-156.709.30Buy
2024-05-276.8910.10Buy
2024-08-215.689.10Buy
2024-11-155.138.00Buy
2025-03-064.867.20Buy
2025-04-015.487.00Buy

Disclosures

  • UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • UBS Securities Hong Kong Limited is a market maker in the Hong Kong-listed securities of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.